| Date Filed | Type | Description |
| 06/16/2023 |
4
| Collins Cynthia (Director) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 19,650 shares
@ $0
Granted 27,350 options to buy
@ $2.47, valued at
$67.6k
|
|
| 06/16/2023 |
4
| Schmid John P. (Director) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 19,650 shares
@ $0
Granted 27,350 options to buy
@ $2.47, valued at
$67.6k
|
|
| 06/16/2023 |
4
| Lloyd Marcea Bland (Director) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 19,650 shares
@ $0
Granted 27,350 options to buy
@ $2.47, valued at
$67.6k
|
|
| 06/16/2023 |
4
| BAUM CHARLES M (Director) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 19,650 shares
@ $0
Granted 27,350 options to buy
@ $2.47, valued at
$67.6k
|
|
| 06/16/2023 |
4
| Corning Luke (Director) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 19,650 shares
@ $0
Granted 27,350 options to buy
@ $2.47, valued at
$67.6k
|
|
| 05/02/2023 |
4
| Amado Rafael (Director) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 39,300 shares
@ $0
Granted 55,200 options to buy
@ $2.76, valued at
$152.4k
|
|
| 04/14/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/02/2023 |
4
| Warner Brent (President, Gene Therapy) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 92,772 shares
@ $0
Paid exercise price by delivering 26,617 shares
@ $5.35, valued at
$142.4k
Granted 125,283 options to buy
@ $5.35, valued at
$670.3k
|
|
| 03/02/2023 |
4
| Mylet Johanna (CFO) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 92,772 shares
@ $0
Paid exercise price by delivering 4,323 shares
@ $5.35, valued at
$23.1k
Granted 125,283 options to buy
@ $5.35, valued at
$670.3k
|
|
| 03/02/2023 |
4
| LEONHARDT HARRY J (GC & Chief Compliance Officer) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 92,772 shares
@ $0
Paid exercise price by delivering 4,323 shares
@ $5.35, valued at
$23.1k
Granted 125,283 options to buy
@ $5.35, valued at
$670.3k
|
|
| 03/02/2023 |
4
| Gergen Mark J (President and CEO) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 269,586 shares
@ $0
Granted 364,060 options to buy
@ $5.35, valued at
$1.9M
|
|
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Corning Luke (Director) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 19,650 shares
@ $0
Granted 28,500 options to buy
@ $2.01, valued at
$57.3k
|
|
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/18/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/18/2022 |
4
| Ingalls Kerry D. (COO) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Bought 3,000 shares
@ $3.98, valued at
$11.9k
|
|
| 03/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/01/2022 |
4
| Ingalls Kerry D. (COO) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 50,000 shares
@ $0
Granted 72,568 options to buy
@ $3.42, valued at
$248.2k
|
|
| 03/01/2022 |
4
| Mylet Johanna (CFO) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 50,000 shares
@ $0
Granted 72,568 options to buy
@ $3.42, valued at
$248.2k
|
|
| 03/01/2022 |
4
| Spear Matthew A. (Chief Medical Officer) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 50,000 shares
@ $0
Granted 72,568 options to buy
@ $3.42, valued at
$248.2k
|
|
| 03/01/2022 |
4
| Warner Brent (President, Gene Therapy) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 307,881 shares
@ $0
Granted 431,034 options to buy
@ $3.42, valued at
$1.5M
|
|
| 03/01/2022 |
3
| Warner Brent (President, Gene Therapy) has filed a Form 3 on Poseida Therapeutics, Inc. |
| 02/01/2022 |
4
| Gergen Mark J (President and CEO) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 357,200 shares
@ $0
Granted 518,500 options to buy
@ $4.75, valued at
$2.5M
|
|
| 02/01/2022 |
4
| Ostertag Eric (Executive Chairman) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Gifted 93,955 shares
@ $0
Gifted 48,902 shares
@ $0
Granted 89,500 shares
@ $0
Granted 118,708 options to buy
@ $4.75, valued at
$563.9k
Granted 10,792 options to buy
@ $0 |
|
| 12/22/2021 |
4
| Mylet Johanna (CFO) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Exercised 2,616 options to buy
@ $1.173, valued at
$3.1k
Exercised 3,100 options to buy
@ $1.933, valued at
$6k
|
|
| 12/08/2021 |
4
| Spear Matthew A. (Chief Medical Officer) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Exercised 10,000 options to buy
@ $1.322, valued at
$13.2k
|
|
| 12/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|